ClinicalTrials.gg
RecruitingNCT06410001Updated Mar 27, 2026

CE-STAND: Cervical Epidural STimulation After Neurologic Damage

A Phase 1/2 interventional study of Epidural Spinal Cord Stimulation System in Spinal Cord Injury, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by University of Minnesota · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Spinal Cord Injuries by University of Minnesota — 7 open to participants now, 7 under way, none of them phase 3. Spinal Cord Injuries · University of Minnesota.

Planned enrollment
7th of 12
36 · median 38
Started
2026
with 1 other
Phase 1/2
2 of 15
1 open now
Registered
13th of 15
by date

Among the 15 studies in Spinal Cord Injuries by University of Minnesota, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 1/2, and was the 13th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

7 of the 15 studies in Spinal Cord Injuries by University of Minnesota are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Spinal Cord Injuries by University of Minnesota, or all of them as a file.
02

Study summary

CE-STAND aims to address three areas under-represented in research: chronic, cervical, and autonomic dysfunction. It is both significant and highly impactful, as treating autonomic dysfunction could substantially improve function and quality of life (QoL) in chronic cervical SCI patients.

Read the detailed description

Spinal cord injury (SCI) affects over 18,000 individuals annually, leading to significant motor and autonomic dysfunctions that reduce quality of life (QoL). Epidural spinal cord stimulation (eSCS) has shown potential in restoring function in chronic individuals with SCI. However, research on cervical, and autonomic dysfunction-related SCI remains limited. This study will assess the safety and efficacy of eSCS in improving autonomic and volitional functions, as well as truncal stability, bowel, bladder, and sexual function, and overall QoL.

The study is a Phase I/II trial in which participants will serve as their own controls. The Abbott Eterna epidural stimulator system will be implanted, and assessments will occur every three months. The study will be conducted over a period of four years. A total of 36 participants will be enrolled and followed for one year.

Bayesian Optimization will be used to determine the most effective stimulation settings, with 15 settings programmed at the end of each visit.

FDA and UMN IRB approvals have been secured for the study. Interim reports will be made available through peer-reviewed journals, conference presentations, and clinical network reporting.

CE-STAND seeks to advance SCI treatment by expanding eSCS applications in chronic cervical SCI, improving patient outcomes, and reducing healthcare costs.

03

Conditions studied

  • Spinal Cord Injury

Keywords

  • Cervical
  • Spinal cord injury
  • Epidural spinal cord stimulation
  • Autonomic dysfunction
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Twenty two years of age or older
  • Able to undergo the /assent process
  • Stable, motor-complete SCI
  • Discrete SCI between C4 and C7 (upper extremity weakness)
  • ASIA A or B SCI Classification
  • Medically stable in the judgment of the PI
  • Intact segmental reflexes below the lesion of injury
  • Greater than 1 year since initial injury and at least 6 months from any required spinal instrumentation
  • Normal or corrected-to-normal vision to accurately perceive visual stimuli on the N-back task screen, and sufficient hearing ability to accurately perceive auditory stimuli during the task
  • Willing to attend all scheduled appointments

Exclusion criteria

Exclusion Criteria:

  • Diseases and conditions that would increase the morbidity and mortality of this surgery such as cardiopulmonary.
  • Individuals who require respiratory support, including ongoing or intermittent use of a ventilator and/or diaphragmatic pacer
  • Inability to withhold antiplatelet/anticoagulation agents perioperatively
  • Individuals who have history of recurrent autonomic dysreflexia in the judgment of the PI
  • Significant dysautonomia that would prohibit rehabilitation or any history of cerebrovascular accident or myocardial infarction associated with autonomic dysreflexia. A single tilt table test with syncope, presyncope, or SBP \< 50 or > 200
  • Failure to exhibit cardiovascular autonomic dysfunction on tilt table testing
  • Other conditions that would make the subject unable to participate in testing/rehabilitation in the judgment of the PI
  • Patients who have participated in another study within the last 12 months in which they have received fluoroscopic or other related radiation exposure
  • Current and anticipated need for opioid pain medications or pain that would prevent full participation in the program in the judgment of the PI
  • mental illness in the judgment of the PI
  • Treatment with botulinum toxin, intrathecal baclofen pump, and antispasmodics will not be permitted unless discussed with and approved by the study PI
  • Patients with a history of significant depression or drug abuse
  • Volitional movements present during EMG testing in bilateral lower extremities
  • Unhealed spinal fracture
  • Presence of significant contracture with loss of greater than two-thirds range of motion
  • Presence of pressure ulcers
  • Current Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Spinal injury patients

    Experimental: Individuals with cervical SCI comparing stimulation "on" vs "off" longitudinally.

    Device: Epidural Spinal Cord Stimulation System

Interventions

  • DeviceEpidural Spinal Cord Stimulation System

    Abbott Eterna system implantable pulse generator (IPG), charger, and TriCentrus lead

06

What researchers measure

Primary outcomes

  1. Safety of epidural spinal cord stimulator in chronic cervical patients

    Incidence of adverse events (AEs) and serious adverse events (SAEs) including hypotension, other hemodynamic instability, infection, bleeding, significant pain, spasticity, or cerebrospinal fluid leak.

    Time frame: 1 year

Secondary outcomes

  1. Changes in blood pressure

    Measured on tilt table testing. Both systolic and diastolic pressure will be assessed

    Time frame: 1 year

  2. Changes in heart rate

    Measured on tilt table testing

    Time frame: 1 year

  3. Cognitive function

    Measured using N-back testing

    Time frame: 1 year

  4. Cerebral blood flow

    Measured using transcranial doppler

    Time frame: 1 year

  5. Muscle Sympathetic Nerve Activities (MSNA)

    Microneurolography

    Time frame: 1 year

Other outcomes

  1. Volitional function on electromyography (EMG)

    Using the modified brain motor control assessment (mBMCA) and electromyography (EMG).

    Time frame: 1 year

  2. Hand function

    The Graded Redefined Assessments of Strength, Sensibility, and Prehension (GRASSP) functional score

    Time frame: 1 year

  3. Truncal stability

    Using the modified Functional reach test (mFRT)

    Time frame: 1 year

  4. Stimulation settings optimization

    Using Bayesian process

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Mansour N, Keller-Ross M, Low W, Balser DY, Parr A. Effect of Cervical Epidural STimulation After Neurological Damage: protocol for phase I/II open label controlled CE-STAND trial. BMJ Open. 2026 Feb 12;16(2):e107661. doi: 10.1136/bmjopen-2025-107661. PubMed 41688122 ↗

Individual participant data

Plan to share: Yes — De-identified data will be deposited in the Data Repository for the University of Minnesota (DRUM), an open-access institutional repository. Data stored during the project will be maintained in Box Secure Storage and REDCap before long-term archiving in DRUM.

Supporting information: Study protocol, Analytic code

Time frame: Data will be shared after publication of the primary results and will remain available for at least 10 years, in accordance with the University of Minnesota's DRUM repository policies.

Access criteria: Data will be openly accessible through DRUM without restrictions.

Data sharing details ↗ · hdl.handle.net

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for May 2030, 50 months after the start.

Of 24 phase 1/2 interventional studies under Spinal Cord Injuries, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 50 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2024
First posted
May 10, 2024
StartActual
Mar 15, 2026
Primary completionEst.
May 31, 2030
CompletionEst.
Jul 30, 2030
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06410001
Responsible party
Sponsor
First posted
May 10, 2024
Start date
Mar 15, 2026
Primary completion
May 31, 2030 (estimated)
Completion
Jul 30, 2030 (estimated)
Last update
Mar 27, 2026

Study contacts

Ann Parr, MD, PhD
Contact
ce-stand@umn.edu
612-625-4102
Nadine Mansour, MD, MPH, PhD
Contact
ce-stand@umn.edu
Ann Parr, MD, PhD
principal investigator · University of Minnesota
Manda Keller-Ross, PhD, DPT, PT
principal investigator · University of Minnesota
Nadine Mansour, MD, MPH, PhD
principal investigator · University of Minnesota

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion